Hantz Financial Services, Inc. Protagonist Therapeutics, Inc Transaction History
Hantz Financial Services, Inc.
- $6.6 Billion
- Q3 2025
A detailed history of Hantz Financial Services, Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 295 shares of PTGX stock, worth $24,959. This represents 0.0% of its overall portfolio holdings.
Number of Shares
295
Previous 143
106.29%
Holding current value
$24,959
Previous $8,000
150.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
302Shares Held
68.6MCall Options Held
139KPut Options Held
40.7K-
Farallon Capital Management LLC San Francisco, CA6.2MShares$524 Million1.78% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$487 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$487 Million5.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$458 Million0.01% of portfolio
-
State Street Corp Boston, MA3.17MShares$268 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $4.15B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...